Results 31 to 40 of about 16,304 (256)

Tendering and biosimilars: what role for value-added services?

Journal of Market Access & Health Policy, 2020
Background: Access to biologic medicines (including biosimilars) across Europe is largely governed by a process of tendering conducted by health authorities. Over-reliance on treatment costs in awarding tenders has the potential to hinder competition and
Steven Simoens, Raymond Cheung
doaj   +1 more source

Biosimilars in Oncology: Latest Trends and Regulatory Status

Pharmaceutics, 2022
Biologic-based medicines are used to treat a variety of diseases and account for around one-quarter of the worldwide pharmaceutical market. The use of biologic medications among cancer patients has resulted in substantial advancements in cancer treatment
Deeksha Joshi, Rubiya Khursheed, Saurabh Gupta, Diksha Wadhwa, Thakur Gurjeet Singh, Sumit Sharma, Sejal Porwal, Swati Gauniyal, Sukriti Vishwas, Sanjay Goyal, Gaurav Gupta, Rajaraman D. Eri, Kylie A. Williams, Kamal Dua, Sachin Kumar Singh   +14 more
doaj   +1 more source

Biosimilars in rheumatology

Pharmacological Research, 2019
Biotechnologicals are an invaluable resource in the treatment of patients with inflammatory rheumatic diseases (IRD) non-responsive or intolerant to conventional therapies. However, they are the main driver for increase in direct costs and represent a significant economic burden to healthcare systems worldwide.
Araújo, Filipe C., Goncalves, Joao, Fonseca, João Eurico   +2 more
openaire   +3 more sources

Biosimilars in the French and Polish System: Chosen Aspects of Reimbursement and Access

Comparative Economic Research, 2020
The EU approved the first biosimilar drug in 2006. By 2017, the EU had authorized the highest number of biosimilars worldwide, acquiring considerable experience in their use and safety.
Olga Barszczewska, Ralph Chami, Anna Piechota   +2 more
doaj   +1 more source

Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany. [PDF]

PLoS ONE, 2017
This study examined gastroenterologists' motivation for prescribing biosimilars, assessed their treatment preferences in relation to prescribing behaviour, and explored patient attitudes to biosimilars.Data were taken from the Adelphi Real World ...
Emma Sullivan, James Piercy, John Waller, Christopher M Black, Sumesh Kachroo   +4 more
doaj   +1 more source

Biosimilar bidding in centralized tenders in Norway

Nordic Journal of Health Economics, 2021
Our objective is to study the competition effect of biosimilar entry in centralized tenders for an expensive category or drugs - TNF-inhibitors. We use monthly observations of prices and volumes for all brands and biosimilars in this drug category in ...
Dag Morten Dalen, Steinar Strøm, Marilena Locatelli   +2 more
doaj   +1 more source

Characterizing the Healthcare Utilization and Costs of Hereditary Hemorrhagic Telangiectasia

American Journal of Hematology, EarlyView.
ABSTRACT Hereditary hemorrhagic telangiectasia (HHT) is the second‐most common inherited bleeding disorder worldwide, afflicting one in 4000–5000 people, and is the most morbid inherited bleeding disorder of women. HHT causes recurrent severe epistaxis, chronic gastrointestinal bleeding, heavy menstrual bleeding, and arteriovenous malformations in the ...
Hanny Al‐Samkari, Tracy J. Mayne, Misty Troutt, Hemant Patle, Marianne Clancy, Eric Duhaime   +5 more
wiley   +1 more source

Biosimilars in oncology

ESMO Open, 2018
Biosimilars will soon become broadly available in the oncology field, raising important questions from both patients and healthcare providers. These questions need to be clarified upfront, in order to increase confidence in using these therapies. In this podcast, Teresa Amaral (Young Oncologist Committee member) talks to Josep Tabernero (ESMO President
openaire   +4 more sources

Biosimilars: Science, Implications, and Potential Outlooks in the Middle East and Africa

Biologics: Targets & Therapy, 2022
Radwa Ahmed Batran,1 Mai Elmoshneb,1 Ahmed Salah Hussein,1,2 Omar M Hussien,1 Fady Adel,1 Reham Elgarhy,1 Mosaad I Morsi1 1Medical Affairs Department, RAY Contract Research Organization, Giza, Egypt; 2Faculty of Medicine, Al-Azhar University, Cairo ...
Batran RA, Elmoshneb M, Hussein AS, Hussien OM, Adel F, Elgarhy R, Morsi MI   +6 more
doaj  

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

Arthritis &Rheumatology, EarlyView.
Objective Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease‐modifying antirheumatic drugs with other modes of action (bDMARD‐OMA) in a multicountry, real‐world population ...
Romain Aymon, Denis Mongin, Romain Guemara, Zubeyir Salis, Johan Askling, Denis Choquette, Catalin Codreanu, Daniela Di Giuseppe, Irini Flouri, Doreen Huschek, Kimme L. Hyrich, Florenzo Iannone, Tore K. Kvien, Burkhard F. Leeb, Dan Nordström, Lucia Otero‐Varela, Karel Pavelka, Manuel Pombo‐Suarez, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Sella A. Provan, Anja Strangfeld, Trokovic Nina, Jakub Zavada, Lianne Kearsley‐Fleet, Delphine S. Courvoisier, Axel Finckh, Kim Lauper   +28 more
wiley   +1 more source